Transcriptome Analysis Identifies ALCAM Overexpression as a Prognosis Biomarker in Laryngeal Squamous Cell Carcinoma

Nicolau-Neto, Pedro; Souza-Santos, Paulo Thiago de; Ramundo, Mariana Severo; Valverde, Priscila; Martins, Ivanir; Santos, Izabella Costa; Dias, Fernando Luiz; Simão, Tatiana de Almeida; Pinto, Luís Felipe Ribeiro

doi:10.3390/cancers12020470

Cited by 16 publications

(20 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using gene microarray analysis, Nicolau-Neto and colleagues [47] have shown that ALCAM is a significant and independent marker for the clinical prognosis of the patients with impressive specificity (94.7%) and sensitivity (93.1%). At the protein level, ALCAM, which was largely confined to the cell membrane, was detected in over 72% of the tumours, and high ALCAM protein levels were linked to a short survival of the patients [47].…”

Section: Head and Neck Scc (Hnscc) And Laryngeal Squamous Cell Carcinoma (Scc)mentioning

confidence: 99%

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Yang

Sanders

Dou

et al. 2021

Cancers

View full text Add to dashboard Cite

Activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, is a cell adhesion protein that is found in multiple cell types. ALCAM has multiple and diverse roles in various physiological and pathological conditions, including inflammation and cancer. There has been compelling evidence of ALCAM’s prognostic value in solid cancers, indicating that it is a potential therapeutic target. The present article overviews the recent findings and progress in ALCAM and its involvement in cancer, with a primary focus on its clinical connections in cancer and therapeutic values.

show abstract

Section: Head and Neck Scc (Hnscc) And Laryngeal Squamous Cell Carcinoma (Scc)mentioning

confidence: 99%

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

Yang

Sanders

Dou

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“… 2 , 3 Although diagnostic strategies have been improved, nearly 60% of LSCC patients are diagnosed at the advanced stages and have poor clinical outcomes. 4 , 5 Therefore, it is an urgent need to investigate the underlying mechanism of LSCC initiation and progression, which will help determine effective therapeutic targets and improve overall prognosis. Currently, existing research has identified a wide variety of dysregulated RNA transcripts, and bioinformatics analysis have suggested that they may be associated with the development of LSCC.…”

Section: Introductionmentioning

confidence: 99%

LncRNA-Associated ceRNA Network Reveals Novel Potential Biomarkers of Laryngeal Squamous Cell Carcinoma

Jing

Guo

Zhang

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective: This study aims to construct a systematic mRNA-miRNA-lncRNA network to identify novel lncRNAs and miRNAs biomarkers for laryngeal squamous cell carcinoma (LSCC). Methods: The mRNA, miRNA and lncRNA expression profiles of LSCC were obtained from Gene Expression Omnibus (GEO) database. The differentially expressed mRNAs, miRNAs and lncRNAs (DEmRNAs, DEmiRNAs and DElncRNAs) were screened between LSCC tissues and controls. Functional analysis of DEmRNAs, DEmRNAs targeted by DEmiRNAs and DEmRNAs targeted by DElncRNAs were respectively performed. The miRWalk, starbase and DIANA-LncBase were respectively used to predict DEmiRNAs-DEmRNAs, DElncRNAs-DEmRNAs and DElncRNAs-DEmiRNAs pairs. ceRNA network was built by DEmiRNAs-DEmRNAs and DElncRNAs-DEmiRNAs pairs. LncRNA subcellular localization was predicted using lncLocator. Using published The Cancer Genome Atlas (TCGA) and external datasets (GSE127165 and GSE133632), we also validated the expression of key DElncRNAs and DEmiRNAs in ceRNA network. The diagnostic and prognostic value of candidate genes was evaluated by ROC curve analysis and survival analysis, respectively. Results: There were 5 mRNA datasets, 3 miRNA datasets and 2 lncRNA datasets in this study. Totally, 2957 DEmRNAs, 61 DElncRNAs and 23 DEmiRNAs were identified. Functional analysis of DEmRNAs shows that they were significantly enriched in cancer-related pathways, such as DNA replication and extracellular matrix organization. There were 11 DEmiRNAs, 17 DElncRNAs and 967 DEmRNAs in the ceRNA network. Notably, up-regulated lncRNA DGCR5-down-regulated has-miR-338-3p/has-miR-139-5p pairs in this network were experimentally validated. Moreover, down-regulated AL121839.2, down-regulated LINC02147, up-regulated AC079328.2, up-regulated AC004943.2 and up-regulated HMGA2-AS1 were located in the cytoplasm. AL121839.2 and LINC02147 interacted with has-miR-1246. AC004943.2, AC079328.2 and HMGA2-AS1 targeted has-miR-3185, has-miR-3137 and has-miR-582-5p, respectively. Based on the TCGA and external datasets (GSE127165 and GSE133632), DGCR5 and AC004943.2 were significantly up-regulated while AL121839.2 and LINC02147, has-miR-338-3p, has-miR-139-5p and has-miR-582-5p were significantly down-regulated, which were consistent with our integration analysis. DGCR5, AL121839.2, LINC02147, AC004943.2, has-miR-338-3p, has-miR-139-5p and has-miR-582-5p could predict the occurrence of LSCC. Survival analysis suggested that only, AL121839.2 has potential prognostic value for LSCC. Conclusion: This study provided novel insights into the ceRNA network and uncovered novel lncRNAs and miRNAs with diagnostic value in LSCC.

show abstract

“…LAMC2 may be a novel target for the treatment or screening of the advantaged population for cetuximab treatment in LC. Besides, we searched the GEO datasets (GSE143224) [18] and analyzed LAMC2 and DMBT1 expression levels in LC.…”

mentioning

confidence: 99%

LAMC2 acts as a novel therapeutic target of cetuximab in laryngeal cancer

Wang¹,

Liu²,

Zhou³

et al. 2021

neo

View full text Add to dashboard Cite

This study was set out to determine the function of LAMC2 in laryngeal cancer (LC). Initially, we identified the expression of LAMC2 in LC cells and tissues using TCGA datasets, GEO datasets (GSE143224), qRT-PCR, and western blot. Besides, we analyzed the correlations between LAMC2 and clinicopathologic features in LC patients. The CCK-8 assays were performed to detect cell viability and the half-maximal inhibitory concentration of cetuximab (IC50) in LC cells. We explored the correlations between LAMC2 and EGFR and further explored the regulation mechanism of cetuximab in LC. This study identified a high expression of LAMC2 in LC cells and tissues. The expression levels of LAMC2 were associated with TNM classification, lymph node (LN) metastasis, differentiation, and overall survival (OS). LAMC2 significantly promoted cell proliferation a nd cell viability. Besides, cetuximab significantly inhibited LAMC2 expression levels. LAMC2 significantly reversed t he effect of cetuximab suppressing cell proliferation in LC cells. In conclusion, LAMC2 may act as a novel anti-cancer target in LC.

show abstract

Transcriptome Analysis Identifies ALCAM Overexpression as a Prognosis Biomarker in Laryngeal Squamous Cell Carcinoma

Cited by 16 publications

References 52 publications

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers

LncRNA-Associated ceRNA Network Reveals Novel Potential Biomarkers of Laryngeal Squamous Cell Carcinoma

LAMC2 acts as a novel therapeutic target of cetuximab in laryngeal cancer

Contact Info

Product

Resources

About